Background: Cisplatin is widely used in combination chemotherapy against a variety of tumors; however, the optimal administration schedule of cisplatin is still controversial. To clarify the pharmacokinetic differences according to the administration schedules of cisplatin, we compared three different administration schedules of cisplatin such as single short-term infusion, daily short-term infusion and daily continuous infusion in combination with 5-fluorouracil. Preliminary clinical responses and toxicities were also investigated. Methods: A total of 12 courses in combination of cisplatin and 5-fluorouracil therapy was studied. The schedules of cisplatin tested were as follows: single short-term infusion (80 mg/m 2 , day 1,2 h div., n =4),daily short-term infusion (20mg/m 2 , days 1 to 5, 2 h div., n =4), daily continuous infusion (100 mg/m 2 , 120 h, n = 4). In all schedules, 5-fluorouracil was continuously administered at a dose of 800 mg/m 2/day on days 1 to 5. The area under the time-concentration curve (AUC) and the maximum concentration (C max ) of total and free Pt were investigated. Results: The highest AUC of total and free Pt and the lowest C max of free Pt were observed in the daily continuous infusion (total AUC; 162.53± 18.39~g h/ml, free AUC; 5.50±0.9~g h/ml, free Cmax; 0.07±0.01 Ilg /ml, mean ± SEM).Two patients in the single short-term infusion and one patient in the daily continuous infusion indicated partial responses clinically. No nephrotoxicity or ototoxicity was observed. All toxicities were mild and tolerable in all regimens; however, the incidence of GI toxicity in daily continuous infusion seemed to be relatively higher. Conclusions: Daily continuous infusion of cisplatin gave the best pharmacokinetic results and to evaluate the clinical advantage of this schedule a prospective randomized trial should be conducted with sufficient numbers of patients.
INTRODUCTION
Cisplatin (CDDP) is one of the important drugs in combination chemotherapy against gastrointestinal tumors (1). A combination of CDDP and 5-fluorouracil (5-FU) (FP) is widely used against esophageal and gastric cancer (2) (3) (4) (5) . In esophageal cancer, FP therapy is considered to be the most potent chemotherapeutic Received August 13, 1997; accepted November 12, 1997 For reprints and all correspondence: Kenichiro Ikeda, Department of Surgery 1, Iwate Medical University, 19-1, Uchimaru, Morioka, 020-0023, Japan regimen with a response rate reported to be between 35 and 60% (2) (3) (4) . FP therapy is also an effective chemotherapeutic regimen against gastric cancer with a response rate of 40% (5) . In this therapy, 4 or 5 days of continuous infusion of 5-FU at a dose of 800-1000 mg/m 2jday and full-dose CDDP ranging from 80 to 100 mg/m-' per course is recommended (2) (3) (4) (5) . However, the administration schedule of CDDP is still controversial. When CDDP is used as a single agent, currently used administration schedules of CDDP are single short-term infusion (6) , daily short-term infusion (6) and daily continuous infusion (7) (8) (9) (10) . The most common administration schedule of CDDP is single short-term infusion, followed by daily short-term infusion. However, Drewinko and co-workers (11, 12) demonstrated thatthecytotoxic effect of CDDPin lowconcentration and long-term exposure was greater than that in high concentration andshort-term exposure in invitro studies. Thisresultmeantthatthe cytotoxic effectof CDDPdepends on the area under the time-concentration curve (AUC). This outcome led clinicians to try protracted infusion of CDDP. Phase I or IT clinical trials of continuous infusion of CDDPas a singleagentagainst several kinds of tumors wereconducted andtheresults suggested thattheresponse rates were equal or superior to those for single short-term infusion. Withregardto the toxicities, although severe thrombocytopenia was observed in continuous infusion, other toxicities such as GI, renal and ototoxicity were milder in continuous infusion than in short-term infusion (7-10). However, a few studies have been conducted to compare the phamacokinetics of CDDP in three different administration schedules. Therefore, we triedto clarify the pharmacokinetic difference in each schedule and we discuss the preliminary pharmacokinetics and pharmacodynamics of CDDP.
MATERIALS AND METHODS

PATIENTS
The subjects included sevenesophageal (six male, one female) and two male gastric cancer patients (Table 1) . The mean age of all patients was 59 (range 49-67). Two esophageal cancerpatients had been treated previously with regimens containing CDDP about 1 monthbeforethis study. Six out of nine patients wereevaluated for clinical response andtheremaining threepatients werenotevaluated because the chemotherapy wasperformed as postoperative adjuvant therapy aftera curative operation. A totalof 12courses of FP therapy wereperformed in these ninepatients andthreeof the ninereceived two different administration schedules (the first course was a daily short-term infusion and the seconda dailycontinuous infusion). In this study, all patients met the following criteria at the beginning of each course: performance status 0-2, normal renal function (serum creatinine <1.2,BUN <20 mg/dl, creatinine clearance >60 ml/min), normal bone marrow function (WBC >4000/mm 3, platelets >I00 OOO/mm 3 ), normal liver function (serum transaminases <60 IUIl, serum total bilirubin <1.5 mg/dl). Furthermore, in patients with previous CDDP treatment, complete recovery from prior toxic effects was required. Informed consent was obtained from all patients included in this study.
ADMINISTRATION SCHEDULE OF FP THERAPY
Central venous catheterswere inserted in the subclavianvein and at least 2500 ml of lactate Ringer solution were infused from 4 to 7 days before the therapy in all patients. In the single short-term infusion schedule, CDDP (80 mg/m 2) diluted in 500 ml of 0.9% sodium chloride (NaCl) solution was drip infused for 2 h on day 1. In the daily short-term infusion schedule, CDDP (20 mg/m-') diluted in 500 ml of NaCI solution was drip infused for 2 h for five consecutive days. In the daily continuous infusion schedule, CDDP (100 mg/m-') diluted in 5000 ml of NaCI solution was drip infused continuously for 120 h. The CDDP solution was shieldedfrom the light during administration.5-FU was continuously drip infused for 120 h from day 1 to day 5 at a dose of 800 mg/m 2/day in each schedule. To obtain sufficient urinary volume, pertinent infusions containing NaCI, potassium chloride and furosemide were administered. Anti-emetic agents such as metoclopramide, methylprednisolone, sodium succinate and 5-HT3 receptor antagonist were also infused as required.
BLOOD AND URINE SAMPLING PROCEDURE TO DETERMINE THE PHARMACOKINETICS OF CDDP Plasma Pt levels were evaluateduntil 24 h after the end of CDDP infusion in all courses. Blood samples were obtained from the cubital vein at 2,2.5,3,4,6,8, 14 and 26 h after the initiationof CDDP infusion in the single short-term infusion. In the daily short-term infusion, blood samples were collected at 2, 3, 8 and 24 h after the initiation of daily infusion. In the daily continuous infusion,blood samples were also obtained at 3,6, 12,24,48, 72, 96, 120 and 144 h after the initiation of CDDP infusion. Blood samples were also obtained before each course. Blood was collected in a heparinized syringe and plasma was immediately separated by centrifugationat 1880 g for 10 min at 4°C. A 2 ml plasma sample was separated and immediately passed through a Centrifree (Amicon, Beverly, MA, USA) at 1880g for 20 min at 4°C in order to obtain the protein-free plasma. Urine samples were collectedfor each 24-h period during five consecutivedays in both daily short-term and daily continuous infusion. In single short-term infusion, urine samples were collected for each 12-h period on dayl and for each 24-h period on the following four days.The protein-freeplasmasamples,the wholeplasmasamples and the urine samples were stored at -80°C until assayed.
PHARMACOKINETIC ANALYSIS OF CDDP
The protein-freeplasma was used for the measurementof free Pt concentration. Total Pt concentration was measured in the whole plasma and the urine samples. Pt concentrations in each sample were determined using a Z-8000R polarized Zeeman atomic absorption spectrometer (Hitachi, Hitachi, Japan), the analytical detection limits of total and free Pt being 0.1 and 0.02 ug/ml, respectively. The areas under the curve (AVe) of total and free Pt were calculatedby the trapezoidal rule during infusion and up to 24 h fromthe end of infusion.The cumulativeurinaryexcretion of total Pt for five consecutivedays was calculatedby converting a dose of CDDP into total Pt.
RENAL FUNCTION PARAMETERS
To determine the possibility of the earlier prediction of renal damageinducedby CDDP, severalrenalfunction parameters such as creatinine clearance (Ccr), free water clearance (C HZo ) , fractional excretion of sodium (FENa), the N-acetylglucosaminidase (NAG) index and fractional excretion of~2-microglobulin (FEBMG) were analyzed for five consecutive days. These parameters were calculated usingthe equations given in the Appendix. C HZo was represented as an absolute value. NAG was quantified colorimetrically using NAG Test Shionogi (Shionogi, Osaka, Japan)and BMG was quantified by a doubleantibody radioimmunoassay(Pharmacia~2-micro RIA; Pharmacia, Uppsala, Sweden). (13); however, the response duration was not taken into consideration. A complete response (CR) was defined as the complete disappearance of all apparent disease as indicated by examinations that were made. A partial response (PR) was defined as a reduction of 250% in the sum of the products of the two greatest perpendicular diameters of all measurable lesions, without the appearance of new lesions. No change (NC) was defined as either a reduction of <50% or an increase of <25% in the sum of the products of the two greatest perpendicular diameters of all measurable lesions, without the appearance of new lesions. Progressive disease (PD) was defined as a >25% increase in tumor measurements or the appearance of any new lesions. The toxicity of these therapies in each course was evaluated by Toxicity Grading Criteria of the Japan Clinical Oncology Group (JCOG) (14) .
STATISTICAL ANALYSES
Data are expressed as means ± SEM. Comparisons of pharmacokinetic and renal function parameters among the groups were based on fractional analysis of variance (ANOVA) followed by
Fisher's protected least significant difference post hoc test and on repeated measure ANOVA followed by a paired r-test, respectively. These statistical analyses were calculated using the computer software Stat View-J 4.5 (Abacus Concepts, Berkeley, CA, USA) for a Macintosh. For a p-value of <0.05, a significant difference was recognized.
RESULTS
PHARMACOKINETICS OF CDDP
Changes in plasma concentration of total and free Pt in each schedule are shown in Figure 1 . In the single short-term infusion, just after the end of infusion, total and free Pt peaked with the highest values at 3.31 ±0.59 and 1.18 ±0.3 llg/ml, respectively.
The plasma concentration of total Pt represented a diphasic change and the half-lives of the ex and~phases were 25 min and 51.9 h, respectively. Free Pt immediately decreased and was not detected 14 h after infusion except for one patient. Furthermore, free Pt was not detected 26 h after infusion in all patients. The half-life of free Pt was calculated as 25.6 min. In the daily short-term infusion, the plasma concentration of total Pt repeatedly increased and decreased and tended to be gradually accumulated. This tendency was also recognized in the free Pt concentrations and no patients had detectable free Pt plasma levels at 8 and 24 h after infusion; however, free Pt levels at 80, 96, 104 and 122 h after infusion were detectable in two or three patients. In the daily continuous infusion, total Pt levels gradually increased from 12 h after infusion. Free Pt was detected in only one patient at 3 and 6 h after infusion. Thereafter, free Pt showed a steady-state concentration at 0.046 llg/ml (mean) from 24 or 48 h to 120 h and the total body clearance of free Pt was calculated as 180.56 ml/min. The pharmacokinetics of CDDP in the three different administration schedules are summarized in Table 2 . Total Pt AUC in the daily short-term infusion and the daily continuous infusion showed statistically significant higher values than that of the single short-term infusion. Free Pt AUC in daily continuous infusion showed a statistically significant higher value than that of the single short-term infusion. Total Pt C max in the single short-term infusion was significantly higher than those of the daily short-term and the daily continuous infusion. With regard to free Pt C max , the single short-term infusion showed the statistically significant highest value [1.13 llg/ml (mean)] and the daily continuous infusion showed the lowest value [0.07 ug/ml (mean)] among these three regimens. Urinary total Pt C max and cumulative urinary excretion of Pt in each schedule appeared to depend on total Pt C max in the plasma. FENa, the NAG index and FEBMG showed no marked changes. However, in the daily short-term infusion, all these parameters gradually increased and the FENaand FEBMG values at 120 h after infusion were statistically higher than those at pre-infusion.
THERAPEUTIC RESPONSE Six patients were evaluated for clinical response and two of them received the daily short-term infusion and the daily continuous infusion sequentially (Table 3) , so eight courses were evaluated for clinical response. Clinical response according to the administration schedules are two PR and one NC in the single short-term infusion, two NC in the daily short-term infusion and one PR and two NC in the daily continuous infusion. Two NC cases in the daily short-term and the daily continuous infusion were the same patients and no obvious differences in clinical response were observed.
TOXICITY
The toxicities according to the treatment schedules are shown in Table 4 . These three schedules were tolerated without any gross signs of toxicity. Neither nephrotoxicity, e.g. elevation of serum BUN or CRNN, nor ototoxicity was observed in any patient. In many patients, bone marrow toxicities were mild. Only two patients showed grade 2 anemia in the daily short-term infusion. Stomatitis was relatively severe in the daily continuous infusion. In two patients who received the daily short-term infusion and daily continuous infusion sequentially, grade 2 stomatitis was recognized in the daily continuous infusion. The incidence of diarrhea was almost equal in each schedule. 
DISCUSSION
Wemeasured plasma concentrations of total and free Pt up to 24 h from the end of CDDP infusion. The total Pt concentration in the single short-term infusion decreased in a diphasic manner, whereas it tended to accumulate in the daily short-term or the daily continuous infusion after completion of CDDP. The free Pt concentration decreased rapidly in all schedules. The calculated pharmacokinetic data showed the highest value of total and free Pt AVC and the lowest value of free Pt C max in the daily continuous infusion. Kurihara et al. (15) reported in a comparative study of the single short-term infusion and the daily short-term infusion of CDDP that the daily short-term infusion indicated higher free Pt AVC. Furthermore, Schellens et al. (16) reported that the free Pt AVC was significantly higher in responders than in non-responders in the same administration schedule of CDDP, hence the cytotoxic effect of CDDP was considered to depend on free Pt AVe. Although the infused dose in the single short-term infusion was 80% smaller than in the other schedules, as far as the pharmacokinetics were concerned, the daily continuous infusion appeared to be the most potent administration schedule of CDDP. In each schedule, the interpatient variability of the pharmacokinetic data was observed. Recently, there have been efforts to develop an optimal therapeutic schedule of chemotherapeutic agents by investigating the pharmacokinetics/pharmacodynamics (PK/PD) correlation (17, 18) . Reece et al. (19) mentioned that repeated courses of CDDP reduced Ccr and increased free Pt AVe. Several investigators also reported that lower Ccr correlated with higher AVC and platelet reduction by CDDP analogs such as carboplatin or 254-S (20) (21) (22) . It is very difficult to discuss the correlation between pharmacokinetic parameters and the pretreatment Ccr in this study, because the number of patients tested was very small (Table 3) . PK/PD analysis with a large number of patients will be required.
Toxicities were mild and almost tolerable in all schedules studied. Nephrotoxicity is one of the most critical effects induced by CDDP. The target cells of CDDP-induced nephrotoxicity are the proximal tubules in the kidneys and its functional parameters are FENa' the NAG index and FEBMG. It is postulated that the earlier changes in these parameters could predict nephrotoxicity induced by CDDP. A significantly higher elevation of FENa and FEBMG was observed only at 120 h after infusion in the daily short-term infusion. Despite these results, no nephrotoxicity or elevation of BUN and CRNN was observed in any patient studied. Hence the clinical significance of the measurement of these parameters for the earlier prediction of nephrotoxicity induced by CDDP was not determined. In general, the nephrotoxicity induced by CDDP is considered to depend on Pt C max (23) . The single short-term infusion indicated a significantly higher value of total and free Pt C max compared with daily short-term or daily continuous infusion; however, no nephrotoxicity was observed in any of the schedules. This was probably due to competent management of the patients.
GI toxicities were often recognized in the daily continuous infusion. There were three patients who received the daily short-term and daily continuous infusion schedules sequentially. In these patients, stomatitis especially was more severe in the daily continuous infusion. Several investigators have reported that GI toxicities in prolonged infusion of CDDP, as a single agent, were equal to or less than those in single short-term infusion (7) (8) (9) (10) . The results of these investigations are different from ours. The reason is considered to be that the toxicity of 5-FU is enhanced by continuous infusion of CDDP. Recent advances, with special reference to the biochemical modulation of 5-FU, revealed that the combination of low-dose CDDP and 5-FU had good therapeutic results against esophageal (24, 25) , gastric (26) and colon (27) cancers. The theoretical mechanism of the enhanced antitumor effect of 5-FU by CDDP is that continuous exposure of cancer cells to low doses of Pt inhibits the cellular uptake of methionine. Consequently, the higher AUC with a steady-state concentration of CDDP achieved by daily continuous infusion may enhance the toxicity of 5-FU in FP therapy.
Our pharmacokinetic study suggests that the daily continuous infusion of CDDP gave the best pharmacokinetic results; however, it was too limited a study to evaluate the therapeutic responses and toxicities and the pharmacokinetics of 5-FU were not investigated either. To evaluate the clinical advantage of daily continuous infusion of CDDP in FP therapy, a prospective randomized trial should be conducted with a sufficient number of patients. Moreover, to develop a more effective and less toxic therapeutic strategy which is suitable for each individual patient, not only drug sensitivity testing (28, 29) to individual tumors but also the PK/pD relationship should be investigated.
APPENDIX
Renal function parameters were calculated by the equations below, with the following abbreviations: U =urinary, S =serum, Cr = creatinine (mg/dl), V = urinary volume (ml/min), P = plasma, osm =osmotic pressure (mOsm), Na =sodium (mequiv./ ml), NAG = N-acetyl-D-glucosaminidase (U/ml) and BMG = 2-microglobulin (ug/ml):
Ccr (ml/min) = (U -Cr/S -Cr) x V C H 0 (ml/min) = 10 -U -osm/P -osm) x VI 2 FENa (%) =(U -Na x S -Cr/S -Na x U -Cr) x 100 FEBMG (%) =(U -BMG x S -Cr/S -BMG x U -Cr) x 100 NAG index (U/mg creatinine) = U -NAG/U -Cr
